| 1. |
2024
YN Liu,WY Chen,KC Jiang,HR Li,ZQ Chen,WH Wang, W Abou-Kheir, YC Wen.
Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer
. Molecular Oncology
.2024
|
|
| 2. |
2024
YN Liu,WY Chen,HL Yeh,WH Chen,KC Jiang,HR Li, PVT Dung, ZQ Chen, WJ Lee, M Hsiao, J Huang, YC Wen.
MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT
. Science Signaling
.2024
;(17):eadc9142--
|
|
| 3. |
2023
Chen WY ,Phan Vu Thuy Dung,Yeh HL ,Chen WH ,Jiang KC ,Li HR, Chen ZQ, Hsiao M , Huang J, Wen YC, Liu YN .
Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer
. Redox Biology
.2023
;(62):102686--
|
|
| 4. |
2023
Wen YC ,Van Thi Ngoc Tram,Chen WH ,Li CH ,Yeh HL ,Phan Vu Thuy Dung, Jiang KC, Li HR , Huang J, Hsiao M ,Chen WY, Liu YN .
CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer
. Cell Death Dis.
.2023
;(14):304--
|
|
| 5. |
2023
Van Thi Ngoc Tram,Hoang Dang Khoa Ta,Gangga Anuraga,Phan Vu Thuy Dung,Do Thi Minh Xuan,Dey Sanskriti, Wang CY, Liu YN .
Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features
. Int J Mol Sci .
.2023
;(24):11930--
|
|
| 6. |
2022
Wen YC,Liu CL,Yeh HL,Chen WH ,Jiang KC,Van Thi Ngoc Tram , Hsiao Michael, Huang Jiaoti, Chen WY, Liu YN.
PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signaling in castration-resistant prostate cancer
. British Journal of Cancer
.2022
;(126):778-790
|
|
| 7. |
2022
Wen YC ,Chen WY ,Van Thi Ngoc Tram,Yeh HL ,Chen WH ,Jiang KC, Abou-Kheir Wassim, Huang J, Hsiao M, Liu YN .
Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency
. Cell Death Dis .
.2022
;(13):252--
|
|
| 8. |
2021
Lin SR,Yeh HL,Liu YN.
Interplay of epidermal growth factor receptor and signal transducer and activator of transcription 3 in prostate cancer: beyond androgen receptor transactivation
. Cancers.
.2021
;(13):3452--
|
|
| 9. |
2021
Chen WY,Wen YC,Lin SR ,Yeh HL ,Jiang KC ,Chen WH,Lin YS, Zhang Q, Liew PL,Hsiao Michael,Huang J, Liu YN .
Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance
. Communications Biology
.2021
;(4):22--
|
|
| 10. |
2021
Wen YC,Liu YN,Yeh HL,Chen WH,Jiang KC,Lin SR, Huang J, Hsiao M, Chen WY.
TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer
. Oncogenesis
.2021
;(10):81--
|
|
| 11. |
2020
EGFR-upregulated LIFR promotes SUCLG2-dependent castration resistance and neuroendocrine differentiation of prostate cancer
. Oncogene
.2020
;(39):6757-6775
|
|
| 12. |
2020
Ras and Wnt interaction contribute in prostate cancer bone metastasis
. Molecules .
.2020
;(25):2380--
|
|
| 13. |
2019
Chen WY,Zeng T,Wen YC,Yeh HL,Jiang KC,Chen WH, Zhang Q, Huang J, Liu YN.
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer
. Cancer Lett.
.2019
;(440-441):35-46
|
|
| 14. |
2019
Liu YN ,Niu S ,Chen WY ,Zhang Q ,Tao Y ,Chen WH, Jiang KC ,Chen X ,Shi H ,Liu A ,Li J ,Li Y ,Lee YC ,Zhang X ,Huang J .
Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46
. Clinical Cancer Research
.2019
;(25):4128-4140
|
|
| 15. |
2019
Bahmad HF,Samman H,Monzer A,Hadadeh O,Cheaito K,Abdel-Samad R, Hayar B, Pisano C, Msheik H, Liu YN, Darwiche N, Abou-Kheir W.
The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells
. Molecular Carcinogenesis
.2019
;(58):1208-1220
|
|
| 16. |
2019
Chao H,Deng L,Xu F,Fu B,Zhu Z, Dong Z, Liu YN, Zeng T.
RAB14 activates MAPK signaling to promote bladder tumorigenesis
. Carcinogenesis
.2019
;(-):1-11
|
|
| 17. |
2019
Fararjeh AbdulFattah Salah ,Liu YN.
ZBTB46, SPDEF, and ETV6: novel potential biomarkers and therapeutic targets in castration-resistant prostate cancer
. Int J Mol Sci.
.2019
;(20):2802--
|
|
| 18. |
2018
Tsai YC,Zeng Tao,Abou-Kheir W,Yeh HL,Lee YC,Yin JJ, Chen WY, Liu YN.
Disruption of ETV6 leads to TWIST1 -dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer
. Molecular Cancer
.2018
;(17):42--
|
|
| 19. |
2018
Tsai YC,Chen WY,Abou-Kheir W,Zeng T,Yin JJ ,Bahmad H, Lee YC, Liu YN.
Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2
. Biochim Biophys Acta - Mol Basis Dis
.2018
;(1864):1717-1727
|
|
| 20. |
2018
Bahmad HF,Cheaito K,Chalhoub RM,Hadadeh O,Monzer A,Ballout F, El-Hajj A, Mukherji D, Liu YN, Daoud G,Abou-Kheir W.
Sphere-formation assay: three-dimensional in vitro culturing of prostate cancer stem/progenitor sphere-forming cells
. Frontiers in Oncology
.2018
;(8):347
|
|
| 21. |
2018
Niu S,Ma X,Zhang Y,Liu YN,Chen X,Gong H,Yao Y, Liu K, Zhang X.
MicroRNA-19a and microRNA-19b promote the malignancy of clear cell renal cell carcinoma through targeting the tumor suppressor RhoB
. PLoS One
.2018
;(13):e0192790
|
|
| 22. |
2017
Tsai YC,Liu YN.
New ideas in preventing castration-resistant prostate cancer
. Oncotarget
.2017
;(8):84628-84629
|
|
| 23. |
2017
Chen WY ,Tsai YC ,Siu MK ,Yeh HL ,Chen CL ,Yin YY, Huang J, Liu YN.
Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis
. Oncogene
.2017
;(36):6213-6224
|
|
| 24. |
2017
Chen WY,Tsai YC,Yeh HL,Suau F,Jiang KC,Shao AN, Huang J, Liu YN.
Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer
. Science Signaling
.2017
;(10):eaam6826--
|
|
| 25. |
2017
Siu MK,Chen WY,Tsai HY,Chen HY,Yin JJ,Chen CL,Tsai YC,Liu YN.
TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer
. Prostate Cancer and Prostatic Diseases
.2017
;(20):172-178
|
|
| 26. |
2017
Tsai YC,Chen WY,Siu MK,Tsai HY,Yin JJ,Huang J,Liu YN.
Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6
. Cancer Lett.
.2017
;(384):1-8
|
|
| 27. |
2016
Chen WY,Hua KT,LeeWJ,Lin YW,Liu YN,Chen CL,Wen YC, Chien MH.
Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy
. Int J Mol Sci.
.2016
;(17):1194
|
|
| 28. |
2016
Siu MK,Chen WY,Tsai HY,Yeh HL,Yin JJ,Liu SY, Liu YN.
Androgen receptor regulates SRC expression through microRNA-203
. Oncotarget
.2016
;(7):25726-25741
|
|
| 29. |
2016
Daoud G,Monzer A,Bahmad H,Chamaa F,Hamdar L,Mouhieddine T, Shayya S, Eid A, Kobeissy F, Liu YN, Abou-Kheir W.
Primary versu castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines
. Oncotarget
.2016
;(7):28961-28975
|
|
| 30. |
2016
Siu MK,Suau F,Chen WY,Tsai YC,Tsai HY,Yeh HL,Liu YN.
KLF4 functions as an activator of the androgen receptor through reciprocal feedback
. Oncogenesis
.2016
;(5):1-12
|
|
| 31. |
2015
Siu MK,Tsai YC,Chang YS,Yin JJ,Suau F,Chen WY, Liu YN.
Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway
. Oncogene
.2015
;(34):4767-4776
|
|
| 32. |
2015
Chang YS,Chen WY,Yin JJ,Tillman H,Huang J,Liu YN.
EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1
. Cancer Research
.2015
;(75):3077-3086
|
|
| 33. |
2015
Chen WY,Huang CY,Cheng WL,Hung CS,Huang MT,Tai CJ,Liu YN,Chen CL,Chang YJ.
Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil
. Tumour Biol.
.2015
;(36):9537-9544
|
|
| 34. |
2015
Chen WY,Liu SY,Chang YS,Yin JJ,Mouhieddine TH,Yeh HL, Abou-Kheir W, Liu YN.
MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer
. Oncotarget
.2015
;(6):441-457
|
|
| 35. |
2015
Liu YN,Yin JJ,Barrett B,Tillman H,Casey O,Fang L,Hynes P, Amir HA, Kelly K.
Loss of androgen regulated miR-1 activates SRC and promotes prostate cancer bone metastasis
. Mol. Cell. Biol.
.2015
;(35):1940-1951
|
|
| 36. |
2014
El-Merahbi R*,Liu YN*,Eid A,Daoud G,Monzer A,Mouhieddine HT, Hosry L, Hamade A, Najjar F, Abou-Kheir W.
Berberis Libanotica Ehrenb extracts show anti-neoplastic effects on Prostate Cancer Stem/Progenitor Cells
. Plos One
.2014
;(9):e11245-e11245
|
|
| 37. |
2014
Abou-Kheir W,Mouhieddine TH,Itani MM,Liu YN.
Bone metastatic prostate cancer and resistance to tyrosine kinase inhibitors: an intimate relationship between loss of miR-203 and up-regulation of EGFR signaling
. RNA& Disease
.2014
;(1):e345
|
|
| 38. |
2014
Siu MK,Abou-Kheir W,Yin JJ,Chang YS,Barrett B,Casey O, Chen WY, Fang L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K.
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance
. Oncotarget
.2014
;(5):3770-3784
|
|
| 39. |
2014
Yin JJ*,Liu YN*,Tillman H*,Barrett B,Hewitt S,Ylaya K, Fang L, Lake R, Corey E, Morrissey C, Vessella R, Kelly K.
AR-regulated TWEAK-FN14 Pathway Promotes Prostate Cancer Bone Metastasis
. Cancer Research
.2014
;(74):4306-4317
|
|
| 40. |
2013
Liu YN,Yin JJ,Abou-Kheir W,Hynes P,Casey O,Fang L, Yi M, Seng V, Tillman H, Martin P, Kelly K.
MiR-1 inhibits EMT via Slug dependent and tumorigenesis via Slug independent mechanisms
. Oncogene
.2013
;(32):296-306
|
|
| 41. |
2012
Liu YN,Abou-Kheir W,Yin JJ,Fang L,Hynes P,Casey O, Hu D, Wan Y, Seng V, Tillman H, Martin P, Kelly K.
Critical and reciprocal regulation of KLF4 and SLUG in TGFbeta-initiated prostate cancer EMT
. Mol. Cell. Biol.
.2012
;(32):941-953
|
|
| 42. |
2011
Martin P,Liu YN,Pierce R,Abou-Kheir W,Camacho D,Simpson M, Kelly K.
Prostate–epithelial specific Pten/TP53 loss leads to tumor heterogeneity resulting from transformation of mutipotential and luminal progenitors and epithelial to mesenchymal transition
. The American Journal of Pathology
.2011
;(179):422-435
|
|
| 43. |
2011
Abou-Kheir W,Hynes P,Martin P,Yin JJ,Liu YN,Seng V, Lake R, Kelly K.
Self-renewing Pten-/-TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity
. Plos One
.2011
;(6):e26112
|
|
| 44. |
2008
Liu YN,Liu Y,Lee HR,Hsu YH,Chen JH.
Activated androgen receptor (AR) down-regulates E-cadherin gene expression and promotes tumor metastasis
. Mol. Cell. Biol.
.2008
;(28):7096-7108
|
|
| 45. |
2005
Liu YN,Lee WW,Wang CY,Chao TH,Chen YV,Chen JH.
Regulatory mechanisms controlling human E-cadherin gene expression
. Oncogene
.2005
;(24):8277-8290
|
|
| 46. |
2004
Liu YN,Kang BB,Chen JH.
Transcriptional regulation of human Osteopontin promoter by C/EBPα and AML-1 in metastatic cancer cells
. Oncogene
.2004
;(23):278-288
|
|
| 47. |
2003
Lu WC,Liu YN,Kang BB,Chen JH.
Trans-activation of Heparanase promoter by ETS transcription factor
. Oncogene
.2003
;(22):919-923
|
|